AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten ratings firms that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $47.13.

ANAB has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. raised their price target on shares of AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a report on Thursday. Wedbush reaffirmed an "outperform" rating and set a $40.00 price target on shares of AnaptysBio in a report on Thursday, May 29th. HC Wainwright upgraded shares of AnaptysBio from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $22.00 to $38.00 in a research note on Wednesday, June 4th. Finally, Guggenheim reiterated a "buy" rating and issued a $90.00 price objective (up previously from $54.00) on shares of AnaptysBio in a research note on Wednesday, May 28th.

Insider Buying and Selling

In other AnaptysBio news, Director Hollings Renton sold 20,925 shares of the firm's stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total transaction of $493,202.25. Following the sale, the director owned 4,965 shares in the company, valued at approximately $117,025.05. This trade represents a 80.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 33.50% of the company's stock.

Institutional Investors Weigh In On AnaptysBio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANAB. Charles Schwab Investment Management Inc. raised its stake in AnaptysBio by 3.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 166,054 shares of the biotechnology company's stock worth $2,199,000 after acquiring an additional 5,733 shares during the period. Swiss National Bank raised its stake in AnaptysBio by 12.1% during the 4th quarter. Swiss National Bank now owns 29,700 shares of the biotechnology company's stock worth $393,000 after acquiring an additional 3,200 shares during the period. KLP Kapitalforvaltning AS bought a new stake in AnaptysBio during the 4th quarter worth approximately $40,000. Vanguard Group Inc. grew its holdings in AnaptysBio by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock valued at $24,411,000 after buying an additional 143,584 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in AnaptysBio by 240.6% during the 4th quarter. JPMorgan Chase & Co. now owns 114,939 shares of the biotechnology company's stock valued at $1,522,000 after buying an additional 81,195 shares in the last quarter.

AnaptysBio Stock Down 0.2%

Shares of NASDAQ ANAB traded down $0.05 during trading on Friday, reaching $26.94. 506,614 shares of the company traded hands, compared to its average volume of 500,929. The firm has a 50 day simple moving average of $23.48 and a 200-day simple moving average of $19.76. The stock has a market capitalization of $791.50 million, a PE ratio of -5.55 and a beta of -0.27. AnaptysBio has a 52-week low of $12.21 and a 52-week high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. The firm had revenue of $27.77 million for the quarter, compared to the consensus estimate of $15.27 million. AnaptysBio had a negative net margin of 125.70% and a negative return on equity of 282.47%. As a group, research analysts predict that AnaptysBio will post -6.08 EPS for the current year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.